Arla Foods Gains FDA Approval for Whey Protein Hydrolysates in Infant Formula
Source: The DairyNews
Arla Foods has successfully obtained FDA approval for the inclusion of whey protein hydrolysates in infant formulas, a significant step forward in allergy management and enhancing gut comfort for infants in the United States.
This approval encompasses four ingredients from Arla Foods Ingredients’ Peptigen® and Lacprodan® lines, officially recognized as meeting the peptone definition per the US Code of Federal Regulations. This authorization enables their use in products designed for early life nutrition.
Anders Steen Jørgensen, Head of the Pediatric Business Unit at Arla Foods Ingredients, remarked on the company's extensive history and commitment to producing high-quality whey protein hydrolysates. “With over 30 years of experience in developing and producing these ingredients at our advanced facilities, we're excited to make them available globally, including to US manufacturers for infant nutrition products aimed at managing cow’s milk allergies or reducing gastrointestinal discomfort,” he said.
The FDA's confirmation covers the usage of Peptigen® IF-3032, Peptigen® IF-3080, Peptigen® IF-3085, and Lacprodan® IF-3070 in early life nutrition products. These ingredients are specifically tailored for different aspects of infant health, ranging from extensively hydrolyzed proteins for managing allergies to partially hydrolyzed proteins that can help infants at high risk of developing milk allergies.
This approval follows successful endorsements in other regions, including the recent EFSA safety and suitability approval for Peptigen® IF-3080 in the EU in 2023. Moreover, Arla Foods Ingredients continues to expand its portfolio, with more hydrolysate products currently in the approval process, reflecting their dedication to supporting the health of formula-fed infants who cannot tolerate traditional milk-based formulas.
Anders Steen Jørgensen, Head of the Pediatric Business Unit at Arla Foods Ingredients, remarked on the company's extensive history and commitment to producing high-quality whey protein hydrolysates. “With over 30 years of experience in developing and producing these ingredients at our advanced facilities, we're excited to make them available globally, including to US manufacturers for infant nutrition products aimed at managing cow’s milk allergies or reducing gastrointestinal discomfort,” he said.
The FDA's confirmation covers the usage of Peptigen® IF-3032, Peptigen® IF-3080, Peptigen® IF-3085, and Lacprodan® IF-3070 in early life nutrition products. These ingredients are specifically tailored for different aspects of infant health, ranging from extensively hydrolyzed proteins for managing allergies to partially hydrolyzed proteins that can help infants at high risk of developing milk allergies.
This approval follows successful endorsements in other regions, including the recent EFSA safety and suitability approval for Peptigen® IF-3080 in the EU in 2023. Moreover, Arla Foods Ingredients continues to expand its portfolio, with more hydrolysate products currently in the approval process, reflecting their dedication to supporting the health of formula-fed infants who cannot tolerate traditional milk-based formulas.
